Samsung Pharmaceutical삼성제약
001360 · KOSPI · ₩001360 · 삼성제약
₩1,251▼ ₩3 (0.24%)End-of-day · Oct 28, 2026 · End-of-day prices.
Margins
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Gross margin | 36.3% | 30.3% | 44.6% | 44.2% | 47.5% | 16.9% |
| Operating margin | −38.1% | −39.2% | −33.5% | −34.7% | −26.9% | −33.0% |
| Net margin | −320.9% | 25.1% | −31.8% | −47.8% | −48.4% | −73.4% |
Growth (year on year)
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue growth | −7.2% | +4.0% | −14.7% | +0.2% | −5.6% | — |
| Operating income growth | +9.8% | −21.8% | +17.8% | −29.2% | +23.0% | — |
| Net income growth | −1,288.0% | +181.9% | +43.2% | +1.1% | +37.7% | — |
Returns
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Return on equity | −141.9% | 10.2% | −15.4% | −27.5% | −21.8% | −31.6% |
| Return on assets | −95.1% | 7.8% | −12.7% | −23.5% | −19.1% | −27.7% |
Leverage and liquidity
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Liabilities to equity | 67.5% | 38.3% | 21.3% | 20.5% | 14.9% | 14.3% |
| Net debt to equity | 6.7% | 0.9% | −6.0% | −5.5% | −34.8% | −20.3% |
| Current ratio | 76.6% | 92.1% | 253.2% | 229.8% | 488.8% | 511.4% |
Calculated from filed financial statements. TTM = trailing 12 months.
Also known as: Samsung Pharmaceutical / 삼성제약 / 001360 / KRX:001360
Source: KRX statistical information